Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Permitted use of Pharma in Focus

Pharma in Focus includes both free and protected content. Free content is available to all users. Protected content is only available to registered users.

Permitted Use of Pharma in Focus protected content

  1. Pharma in Focus protected content is for the personal use of registered users only. Registered users are those who have paid a subscription for access to protected content. Protected content is any content not made available free of charge on the Pharma in Focus site or via the Pharma in Focus News Alert email.

  2. Registered users may:

    a) Access Pharma in Focus material either from their workplace computer or at home or at a remote computer if away temporarily.

    b) Make one hard copy for personal use

    c) Use the 'email a friend' facility in keeping with condition 3(a) below

  1. Registered users may not:

    a) use the 'email a friend' facility to redistribute Pharma in Focus as a whole or in any quantity or frequency which amounts to any person having substantially the benefit of unrestricted access to Pharma in Focus without having paid a subscription or having a subscription paid on their behalf

    b) use their registered email address, or permit it to be used, to allow others gain access to Pharma in Focus

    c) redistribute Pharma in Focus material to anyone by any other means.

TOP | BACK

Perspective
Queue for PBS listing stretches back years
With drugs waiting in the wings for PBS listing more than two and a half years after being recommended, the road to reimbursement remains a long and winding one and for some, it's a road to nowhere.
Approvals Action
Pfizer registers meningo B vax
Pfizer has registered meningococcal B vax Trumenba on the ARTG making it the second vaccine for the disease after GSK's Bexsero.
Pipeline Monitor
GSK, AZ gear up for COPD filing
Big data readouts this week saw GSK and AstraZeneca confirming they would file existing drugs in the COPD space within the next 12 months.